Episurf Medical appointed Siaca Medical as its distributor in Australia and New Zealand for technologies including the Episealer® Knee and the Episealer® Talus. Episurf is currently engaged in regulatory work in the region. Sales in New Zealand are slated to begin in 2021, followed by sales in Australia in 2022.
“These are highly interesting orthopaedic markets, and we are pleased with having a strong partner on the ground. We are currently focusing on the regulatory work leading to market access, and we hope to be able to offer our products to orthopaedic surgeons in the region as soon as possible,” said Pål Ryfors, CEO of Episurf Medical.
Episurf Medical appointed Siaca Medical as its distributor in Australia and New Zealand for technologies including the Episealer® Knee and the Episealer® Talus. Episurf is currently engaged in regulatory work in the region. Sales in New Zealand are slated to begin in 2021, followed by sales in Australia in 2022.
“These are highly interesting...
Episurf Medical appointed Siaca Medical as its distributor in Australia and New Zealand for technologies including the Episealer® Knee and the Episealer® Talus. Episurf is currently engaged in regulatory work in the region. Sales in New Zealand are slated to begin in 2021, followed by sales in Australia in 2022.
“These are highly interesting orthopaedic markets, and we are pleased with having a strong partner on the ground. We are currently focusing on the regulatory work leading to market access, and we hope to be able to offer our products to orthopaedic surgeons in the region as soon as possible,” said Pål Ryfors, CEO of Episurf Medical.
Copy to clipboard 
